All 1 tracked stories fall under one category: regulation. 4D Medical is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 5 original sources each against 2.8 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about CSL
All 1 tracked stories fall under one category: regulation. 4D Medical is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 5 original sources each against 2.8 for the same window. Their average consequence score of 6 runs above the beat's 5.7 for that window. CSL appears in 1 tracked Finance story from February 25, 2026.
Stories tracked
1
Sources per story
5
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 96 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering CSL. Shared-story counts are live from our verified record — not editorial picks.
The global healthcare sector is splitting into a 'two-speed' market as regulatory uncertainty under the Trump administration pressures established giants while innovative biotechs find significant capital. Despite a 25% decline in the ASX 200 healthcare index, smaller players are leveraging AI and record-setting capital raises to navigate a complex FDA landscape.
CSL is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.